MedPath

EDP-1815

Generic Name
EDP-1815
Clinical Trials
Related News

Evaluation of the Immunopharmacology of EDP1815 and EDP2939

Phase 1
Completed
Conditions
KLH and Imiquimod Induced Skin Inflammation in Healthy Volunteers
Interventions
Drug: Placebo oral capsule
First Posted Date
2023-01-12
Last Posted Date
2023-05-19
Lead Sponsor
Evelo Biosciences, Inc.
Target Recruit Count
38
Registration Number
NCT05682222
Locations
πŸ‡³πŸ‡±

Centre for Human Drug Research, Leiden, Netherlands

A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

Phase 2
Terminated
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2022-06-30
Last Posted Date
2023-09-07
Lead Sponsor
Evelo Biosciences, Inc.
Target Recruit Count
287
Registration Number
NCT05439941
Locations
πŸ‡ΊπŸ‡Έ

USA -101, Fort Lauderdale, Florida, United States

πŸ‡§πŸ‡¬

BGR-105, Pleven, Bulgaria

πŸ‡ΊπŸ‡Έ

USA-121, Columbus, Ohio, United States

and more 51 locations

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2021-11-16
Last Posted Date
2023-08-16
Lead Sponsor
Evelo Biosciences, Inc.
Target Recruit Count
421
Registration Number
NCT05121480
Locations
πŸ‡ΊπŸ‡Έ

USA-112, Fountain Valley, California, United States

πŸ‡ΊπŸ‡Έ

USA-114, Newport Beach, California, United States

πŸ‡ΊπŸ‡Έ

USA-105, Miramar, Florida, United States

and more 56 locations

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Phase 2
Completed
Conditions
Plaque Psoriasis
Psoriasis
Interventions
Drug: Placebo
First Posted Date
2020-10-26
Last Posted Date
2022-12-19
Lead Sponsor
Evelo Biosciences, Inc.
Target Recruit Count
249
Registration Number
NCT04603027
Locations
πŸ‡ΊπŸ‡Έ

Synexus Clinical Research US, Inc. - St. Petersburg, Saint Petersburg, Florida, United States

πŸ‡΅πŸ‡±

Synexus - Gdynia, Gdynia, Pomorskie, Poland

πŸ‡΅πŸ‡±

Synexus - Warszawa, Warszawa, Poland

and more 23 locations

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

Phase 2
Terminated
Conditions
Covid19
Interventions
Drug: Placebo
First Posted Date
2020-07-28
Last Posted Date
2022-12-19
Lead Sponsor
Evelo Biosciences, Inc.
Target Recruit Count
16
Registration Number
NCT04488575
Locations
πŸ‡ΊπŸ‡Έ

DHR Health Institute, Edinburg, Texas, United States

πŸ‡ΉπŸ‡·

Hacettepe University Adult Hospital, Ankara, Turkey

πŸ‡ΊπŸ‡Έ

The University Hospital, Newark, New Jersey, United States

and more 1 locations

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

Phase 2
Completed
Conditions
COVID-19
Interventions
Other: Standard of care
First Posted Date
2020-05-19
Last Posted Date
2023-07-28
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
454
Registration Number
NCT04393246
Locations
πŸ‡¬πŸ‡§

Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Phase 1
Completed
Conditions
Psoriasis
Atopic Dermatitis
Interventions
Drug: Placebo oral capsule
Drug: Placebo oral tablet
First Posted Date
2018-11-07
Last Posted Date
2022-01-10
Lead Sponsor
Evelo Biosciences, Inc.
Target Recruit Count
204
Registration Number
NCT03733353
Locations
πŸ‡¬πŸ‡§

UK-7, Blackpool, United Kingdom

πŸ‡¬πŸ‡§

UK-5, Liverpool, United Kingdom

πŸ‡¬πŸ‡§

UK-8, Barnsley, United Kingdom

and more 6 locations
Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy